1 / 11

Aarkstore - Metastatic Hormone Refractory

Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Browse full report @ http://bit.ly/1Ms2HSk

JustinSterling
Download Presentation

Aarkstore - Metastatic Hormone Refractory

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Pharmaceuticals and Healthcare Aarkstore - Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  2. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. A key objective of DelveInsights report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs falling under Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Browse Complete Report – http://www.aarkstore.com/pharmaceuticals-healthcare/98051/metastatic-hormone-refractory-castration-resistant-androgen-independent-prostate-cancer-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape-20155

  3. Data Sources • The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts. • Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases. • Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. .

  4. Scope • A snapshot of the global Market therapeutics scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. • A review of the marketed products under prescription for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, regulatory information and marketing status. • Coverage of global patent coverage and detailed commentaries on the US patent challenges. • Graphical representation of investigational products for patent expiry and market exclusivities across the globe. • Product profiles for marketed products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details. • Coverage of API Manufacturers for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer drugs in the United States, Europe and Asian Regions with location details.

  5. Reasons to buy • A snapshot of the global Market therapeutics scenario for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. • A review of the marketed products under prescription for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, regulatory information and marketing status. • Coverage of global patent coverage and detailed commentaries on the US patent challenges. • Graphical representation of investigational products for patent expiry and market exclusivities across the globe. • Product profiles for marketed products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

  6. Table of Content • Indication Overview • Marketed Drugs • Marketed Details of Drugs by Application Type • Marketed Details of Drugs (NDA) by Marketing Status • Marketed Details of Drugs by Patent Expiration Timeline • Active Pharmaceutical Ingredient (API) Manufacturers Assessment • API Manufacturers by United States Drug Master File (US DMF) Status • API Manufacturers by US DMF Status (Drug Specific) • API Manufacturers in Europe by Country • API Manufacturers in India by State • API Manufacturers in China by Province • Marketed Details of Approved Drugs by Geography • Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs

  7. List of Tables • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type, 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status, 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status, 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Drugs, API Manufacturers, Europe by Country, 2015

  8. List of Figures • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Application Type (%), 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutic Market, US, (Year), 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, API Manufacturers by US DMF Status (%), 2015 • Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Marketed Drugs, US DMF Status Drug Specific (Number), 2015

  9. Related reports: • Pharmaceutical Industry Business Confidence Report H1 2015 • Steatohepatitis Global Clinical Trials Review, H1, 2015 • Post Operative Nausea And Vomiting Global Clinical Trials Review, H1, 2015 • Nonerosive Reflux Disease (NERD) Global Clinical Trials Review, H1, 2015 • Nonerosive Reflux Disease (NERD) Global Clinical Trials Review, H1, 2015 • Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015 • Patient Monitoring and Diagnostic Systems Markets in China • Hearing Aids Markets in China • Medical Imaging System and Equipment Markets in China • Medical Devices Markets in China

  10. Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015 Published: Feb 2015 | 100 Pages Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer. Price

  11. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related